Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APIRx-1602
- Development stage
- Unknown
- Lead developer
- Incannex Healthcare
- Administration
- Topical
01
Overview
**APIRx-1602** is a proprietary topical pharmaceutical formulation developed by APIRx Pharmaceuticals (acquired by Incannex Healthcare) for the treatment of **psoriasis**, targeting the $0.5 billion global market. It has completed a **Phase 2A clinical trial**, with pre-IND activities underway, leveraging APIRx's patented cannabinoid-based delivery technologies for skin conditions. Specific details on active ingredients, mechanism of action, or trial results are not publicly detailed in available sources, positioning it as a preclinical-to-early clinical asset in Incannex's dermatology portfolio alongside candidates for vitiligo and atopic dermatitis.[3][5][6][7][9][12][15]
Beyond the preview
Go deeper on APIRx-1602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APIRx-1602.